Investigation of the anticancer mechanism of monensin via apoptosis-related factors in SH-SY5Y neuroblastoma cells.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
29
06
2023
received:
31
03
2023
accepted:
30
06
2023
medline:
15
9
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Monensin is an ionophore antibiotic that inhibits the growth of cancer cells. The aim of this study was to investigate the apoptosis-mediated anticarcinogenic effects of monensin in SH-SY5Y neuroblastoma cells. The effects of monensin on cell viability, invasion, migration, and colony formation were determined by XTT, matrigel-chamber, wound healing, and colony formation tests, respectively. The effects of monensin on apoptosis were determined by real-time polymerase chain reaction, TUNEL, Western blot, and Annexin V assay. We have shown that monensin suppresses neuroblastoma cell viability, invasion, migration, and colony formation. Moreover, we reported that monensin inhibits cell viability by triggering apoptosis of neuroblastoma cells. Monensin caused apoptosis by increasing caspase-3, 7, 8, and 9 expressions and decreasing Bax and Bcl-2 expressions in neuroblastoma cells. In Annexin V results, the rates of apoptotic cells were found to be 9.66 ± 0.01% (p < 0.001), 29.28 ± 0.88% (p < 0.01), and 62.55 ± 2.36% (p < 0.01) in the 8, 16, and 32 μM monensin groups, respectively. In TUNEL results, these values were, respectively; 35 ± 2% (p < 0.001), 34 ± 0.57% (p < 0.001), and 75 ± 2.51% (p < 0.001). Our results suggest that monensin may be a safe and effective therapeutic candidate for treating pediatric neuroblastoma.
Identifiants
pubmed: 37477356
doi: 10.1111/cts.13593
pmc: PMC10499413
doi:
Substances chimiques
Monensin
906O0YJ6ZP
Annexin A5
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1725-1735Informations de copyright
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Oncogene. 2003 Nov 24;22(53):8543-67
pubmed: 14634618
Chem Biol Drug Des. 2015 Dec;86(6):1378-86
pubmed: 26058448
Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118688
pubmed: 32087180
J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9
pubmed: 10363850
Oncogene. 2006 Aug 7;25(34):4798-811
pubmed: 16892092
Int J Oncol. 2003 Jul;23(1):197-204
pubmed: 12792794
Curr Top Med Chem. 2018;18(22):1976-1986
pubmed: 30499391
Med Res Rev. 2021 Mar;41(2):961-1021
pubmed: 33155698
Br J Haematol. 2002 Nov;119(2):400-7
pubmed: 12406077
Int J Cancer. 2002 Sep 20;101(3):235-42
pubmed: 12209973
Children (Basel). 2021 Jun 07;8(6):
pubmed: 34200194
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
J Exp Clin Cancer Res. 2020 May 6;39(1):78
pubmed: 32375866
Clin Transl Sci. 2023 Sep;16(9):1725-1735
pubmed: 37477356
Int J Oncol. 2003 Apr;22(4):855-60
pubmed: 12632079
Mol Cancer Ther. 2010 Dec;9(12):3175-85
pubmed: 21159605
BMC Cell Biol. 2013 Jul 09;14:32
pubmed: 23834359
Sci Rep. 2017 Jun 8;7(1):3091
pubmed: 28596528
Sci Rep. 2018 Dec 17;8(1):17914
pubmed: 30559409
In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):736-742
pubmed: 30324243
Drug Dev Res. 2020 Sep;81(6):745-753
pubmed: 32462716
PLoS One. 2014 Oct 16;9(10):e110610
pubmed: 25330190
Urol Clin North Am. 2000 Aug;27(3):383-92, vii
pubmed: 10985139
Mol Cancer Ther. 2014 Apr;13(4):812-22
pubmed: 24552772
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Surg Oncol. 2007 Nov;16(3):149-56
pubmed: 17976976
Sci Rep. 2015 Dec 17;5:18144
pubmed: 26674674
J Biomed Sci. 2017 Feb 8;24(1):14
pubmed: 28178969
Cancer Causes Control. 1999 Dec;10(6):539-49
pubmed: 10616823
Tuberc Respir Dis (Seoul). 2013 Jul;75(1):9-17
pubmed: 23946753
Anticancer Res. 2016 Nov;36(11):5835-5843
pubmed: 27793906
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1549-1554
pubmed: 31054863